<code id='8860CF4AEB'></code><style id='8860CF4AEB'></style>
    • <acronym id='8860CF4AEB'></acronym>
      <center id='8860CF4AEB'><center id='8860CF4AEB'><tfoot id='8860CF4AEB'></tfoot></center><abbr id='8860CF4AEB'><dir id='8860CF4AEB'><tfoot id='8860CF4AEB'></tfoot><noframes id='8860CF4AEB'>

    • <optgroup id='8860CF4AEB'><strike id='8860CF4AEB'><sup id='8860CF4AEB'></sup></strike><code id='8860CF4AEB'></code></optgroup>
        1. <b id='8860CF4AEB'><label id='8860CF4AEB'><select id='8860CF4AEB'><dt id='8860CF4AEB'><span id='8860CF4AEB'></span></dt></select></label></b><u id='8860CF4AEB'></u>
          <i id='8860CF4AEB'><strike id='8860CF4AEB'><tt id='8860CF4AEB'><pre id='8860CF4AEB'></pre></tt></strike></i>

          Home / knowledge / explore

          explore


          explore

          author:explore    Page View:4645
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In